Rothermundt, Christian; Andreou, Dimosthenis; Blay, Jean-Yves; Brodowicz, Thomas; Desar, Ingrid M E; Dileo, Palma; Gelderblom, Hans; Haas, Rick; Jakob, Jens; Jones, Robin L; Judson, Ian; Kunz, Wolfgang G; Liegl-Atzwanger, Berndadette; Lindner, Lars H; Messiou, Christina; Miah, Aisha B; Reichardt, Peter; Szkandera, Joanna; van der Graaf, Winette T A; van Houdt, Winan J; ... (2023). Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022. European journal of cancer, 180, pp. 158-179. Elsevier 10.1016/j.ejca.2022.11.008
|
Text
1-s2.0-S0959804922013442-main.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (1MB) | Preview |
BACKGROUND
Owing to the rarity and heterogeneity in biology and presentation, there are multiple areas in the diagnosis, treatment and follow-up of soft tissue sarcoma (STS), with no, low-level or conflicting evidence.
METHODS
During the first Consensus Conference on the State of Science in Sarcoma (CSSS), we used a modified Delphi process to identify areas of controversy in the field of sarcoma, to name topics with limited evidence-based data in which a scientific and knowledge gap may remain and a consensus statement will help to guide patient management. We determined scientific questions which need to be addressed in the future in order to generate evidence and to inform physicians and caregivers in daily clinical practice in order to improve the outcomes of patients with sarcoma. We conducted a vote on STS key questions and controversies prior to the CSSS meeting, which took place in May 2022.
RESULTS
Sixty-two European sarcoma experts participated in the survey. Sixteen strong consensus (≥95%) items were identified by the experts, as well as 30 items with a ≥75% consensus on diagnostic and therapeutic questions. Ultimately, many controversy topics remained without consensus.
CONCLUSIONS
In this manuscript, we summarise the voting results and the discussion during the CSSS meeting. Future scientific questions, priorities for clinical trials, registries, quality assurance, and action by stakeholders are proposed. Platforms and partnerships can support innovative approaches to improve management and clinical research in STS.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1879-0852 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Teuta Bytyqi |
Date Deposited: |
08 Jan 2024 10:06 |
Last Modified: |
08 Jan 2024 10:06 |
Publisher DOI: |
10.1016/j.ejca.2022.11.008 |
PubMed ID: |
36599184 |
Additional Information: |
Writing committee on behalf of CSSS panellists: Kollár, Attila |
Uncontrolled Keywords: |
Consensus Diagnosis Imaging Multimodal treatment Peri-operative management Policy Soft tissue sarcoma Surveillance Treatment of advanced disease |
BORIS DOI: |
10.48350/191284 |
URI: |
https://boris.unibe.ch/id/eprint/191284 |
Actions (login required)
 |
Edit item |